InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
2.470
+0.090 (3.78%)
May 15, 2026, 4:00 PM EDT - Market closed
InflaRx Employees
InflaRx had 65 employees as of December 31, 2025. The number of employees decreased by 9 or -12.16% compared to the previous year.
Employees
65
Change (1Y)
-9
Growth (1Y)
-12.16%
Revenue / Employee
$520
Profits / Employee
-$761,202
Market Cap
363.81M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 65 | -9 | -12.16% |
| Dec 31, 2024 | 74 | 12 | 18.97% |
| Dec 31, 2023 | 62 | 18 | 40.41% |
| Dec 31, 2022 | 44 | -12 | -20.75% |
| Dec 31, 2021 | 56 | 9 | 18.18% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Vanda Pharmaceuticals | 533 |
| Rocket Pharmaceuticals | 202 |
| Puma Biotechnology | 179 |
| Invivyd | 122 |
| Verastem | 102 |
| Larimar Therapeutics | 71 |
| Rezolute | 68 |
| X4 Pharmaceuticals | 45 |
IFRX News
- 4 days ago - InflaRx upgraded to Strong Buy from Outperform at Raymond James - TheFly
- 6 days ago - InflaRx price target raised to $8 from $6 at H.C. Wainwright - TheFly
- 9 days ago - InflaRx Transcript: Investor update - Transcripts
- 9 days ago - InflaRx Announces Closing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire
- 11 days ago - InflaRx to develop izicopan in AAV - TheFly
- 11 days ago - InflaRx Announces Pricing of $150 Million Underwritten Offering of Ordinary Shares - GlobeNewsWire
- 11 days ago - InflaRx Announces Advancement of Izicopan in ANCA-Associated Vasculitis and Select Renal Diseases - GlobeNewsWire
- 13 days ago - InflaRx announces new izicopan pre-clinical data - TheFly